Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Neoplasms 2Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Liposarcoma 1Leukemia 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × plitidepsin × Clear all
NCT00780975 2020-11-24

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

PharmaMar

Phase 2 Terminated
8 enrolled 9 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00780143 2018-11-09

Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia

PharmaMar

Phase 1/2 Terminated
3 enrolled 6 charts
Other hematologic neoplasm

Leukemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡